UA113733C2 - Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу - Google Patents

Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу Download PDF

Info

Publication number: UA113733C2
Authority: UA; Ukraine
Prior art keywords: still; type; соон; compound; structural units
Prior art date: 2011-05-17

Application number

UAA201313464A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-17

Filing date

2012-05-17

Publication date

2017-03-10

2012-05-17 Application filed filed Critical

2012-05-17 Priority claimed from PCT/IB2012/052483 external-priority patent/WO2012156938A1/ru

2017-03-10 Publication of UA113733C2 publication Critical patent/UA113733C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 78
150000001875 compounds Chemical class 0.000 title claims abstract description 65
230000002265 prevention Effects 0.000 title claims abstract description 30
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
230000015572 biosynthetic process Effects 0.000 claims abstract description 34
239000003814 drug Substances 0.000 claims abstract description 30
229940079593 drug Drugs 0.000 claims abstract description 23
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 23
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
201000010099 disease Diseases 0.000 claims abstract description 17
239000003085 diluting agent Substances 0.000 claims abstract description 8
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 claims abstract description 7
239000003937 drug carrier Substances 0.000 claims abstract description 7
239000003795 chemical substances by application Substances 0.000 claims abstract description 6
230000000694 effects Effects 0.000 claims description 19
229920001577 copolymer Polymers 0.000 claims description 18
230000006378 damage Effects 0.000 claims description 17
229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 claims description 14
210000002151 serous membrane Anatomy 0.000 claims description 10
229920001661 Chitosan Polymers 0.000 claims description 7
239000008280 blood Substances 0.000 claims description 6
210000004369 blood Anatomy 0.000 claims description 6
229920002873 Polyethylenimine Polymers 0.000 claims description 5
238000002357 laparoscopic surgery Methods 0.000 claims description 4
229920002717 polyvinylpyridine Polymers 0.000 claims description 3
229920003169 water-soluble polymer Polymers 0.000 claims description 3
210000000416 exudates and transudate Anatomy 0.000 claims description 2
239000008174 sterile solution Substances 0.000 claims description 2
101100367084 Caenorhabditis elegans such-1 gene Proteins 0.000 claims 4
244000005894 Albizia lebbeck Species 0.000 claims 3
125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
230000002378 acidificating effect Effects 0.000 claims 2
101500020117 Aedes aegypti Sialokinin Proteins 0.000 claims 1
102100035472 DNA polymerase iota Human genes 0.000 claims 1
244000068988 Glycine max Species 0.000 claims 1
235000010469 Glycine max Nutrition 0.000 claims 1
101001094672 Homo sapiens DNA polymerase iota Proteins 0.000 claims 1
101150065603 PLEK gene Proteins 0.000 claims 1
239000000428 dust Substances 0.000 claims 1
210000005069 ears Anatomy 0.000 claims 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
230000009545 invasion Effects 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 15
230000002980 postoperative effect Effects 0.000 abstract description 8
230000000181 anti-adherent effect Effects 0.000 abstract description 2
241001465754 Metazoa Species 0.000 description 34
230000008569 process Effects 0.000 description 33
239000000243 solution Substances 0.000 description 27
210000000683 abdominal cavity Anatomy 0.000 description 26
229920000642 polymer Polymers 0.000 description 19
239000007864 aqueous solution Substances 0.000 description 17
230000000968 intestinal effect Effects 0.000 description 15
150000003839 salts Chemical class 0.000 description 14
239000000499 gel Substances 0.000 description 11
210000000056 organ Anatomy 0.000 description 9
238000010186 staining Methods 0.000 description 9
229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
239000001768 carboxy methyl cellulose Substances 0.000 description 8
235000010948 carboxy methyl cellulose Nutrition 0.000 description 8
239000008112 carboxymethyl-cellulose Substances 0.000 description 8
210000004303 peritoneum Anatomy 0.000 description 8
239000000203 mixture Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
208000014674 injury Diseases 0.000 description 6
238000011160 research Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
241000700159 Rattus Species 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
239000007921 spray Substances 0.000 description 5
210000003815 abdominal wall Anatomy 0.000 description 4
238000010171 animal model Methods 0.000 description 4
-1 polytetrafluoroethylene Polymers 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
238000005303 weighing Methods 0.000 description 4
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
102000043136 MAP kinase family Human genes 0.000 description 3
108091054455 MAP kinase family Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000013543 active substance Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000011888 autopsy Methods 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
210000002808 connective tissue Anatomy 0.000 description 3
229940119743 dextran 70 Drugs 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000010562 histological examination Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000000178 monomer Substances 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
239000004584 polyacrylic acid Substances 0.000 description 3
238000011477 surgical intervention Methods 0.000 description 3
230000008733 trauma Effects 0.000 description 3
210000001835 viscera Anatomy 0.000 description 3
210000000504 visceral peritoneum Anatomy 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
206010060932 Postoperative adhesion Diseases 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
210000004534 cecum Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000036541 health Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000009736 wetting Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
206010000050 Abdominal adhesions Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
108010088842 Fibrinolysin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010019670 Hepatic function abnormal Diseases 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
238000004026 adhesive bonding Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940124623 antihistamine drug Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940001501 fibrinolysin Drugs 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
210000003281 pleural cavity Anatomy 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000004088 simulation Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UAA201313464A 2011-05-17 2012-05-17 Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу UA113733C2 (xx)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
RU2011119848/15A RU2011119848A (ru)	2011-05-17	2011-05-17	Способ профилактики спайкообразования
PCT/IB2012/052483 WO2012156938A1 (ru)	2011-05-17	2012-05-17	Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса

Publications (1)

Publication Number	Publication Date
UA113733C2 true UA113733C2 (xx)	2017-03-10

Family

ID=49254499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA201313464A UA113733C2 (xx)	2011-05-17	2012-05-17	Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу

Country Status (4)

Country	Link
CU (1)	CU20130154A7 (es)
MY (1)	MY198042A (es)
RU (1)	RU2011119848A (es)
UA (1)	UA113733C2 (es)

2011
- 2011-05-17 RU RU2011119848/15A patent/RU2011119848A/ru unknown
2012
- 2012-05-17 MY MYPI2014000195A patent/MY198042A/en unknown
- 2012-05-17 UA UAA201313464A patent/UA113733C2/uk unknown
2013
- 2013-11-18 CU CU2013000154A patent/CU20130154A7/es unknown

Also Published As

Publication number	Publication date
CU20130154A7 (es)	2014-05-27
RU2011119848A (ru)	2012-11-27
MY198042A (en)	2023-07-27

Publication	Publication Date	Title
EP3228331B1 (en)	2020-05-27	Biocompatible hemostatic product and preparation method thereof
CN101267831B (zh)	2013-04-24	用于促进止血和其它生理活动的组合物和方法
US10549008B2 (en)	2020-02-04	Method for preparing wound dressing material using biopolymer and wound dressing material using biopolymer prepared thereby
Tan et al.	2021	Enlisting a Traditional Chinese Medicine to tune the gelation kinetics of a bioactive tissue adhesive for fast hemostasis or minimally invasive therapy
EP3777875B1 (en)	2025-12-03	Surgical methods employing purified amphiphilic peptide compositions
RU2680959C2 (ru)	2019-03-01	Композиции и применение противомикробных материалов со свойствами биологической совместимости
CN101472620A (zh)	2009-07-01	用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法
US20130098550A1 (en)	2013-04-25	Functionalized adhesive for medical devices
KR20190084840A (ko)	2019-07-17	온도 감응성 고분자 조성물
AU2017221883B2 (en)	2019-06-20	Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
BICK	1942	Observations on the Topical Use of Sulfonamide Derivatives
RU2624228C1 (ru)	2017-07-03	Соединения для лечения или профилактики спайкообразования, фармацевтические композиции на их основе и способ профилактики и лечения спаечного процесса
ES2746250T3 (es)	2020-03-05	Compuestos para la profilaxis y tratamiento del proceso de adherencia
US20190269820A1 (en)	2019-09-05	Biological adhesives and sealants and methods of using the same
RU2262942C2 (ru)	2005-10-27	Способ обтурации наружных трубчатых свищей пищеварительного тракта и остаточных полостей абдоминальной области
NZ618882B2 (en)	2016-07-01	Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
HK1189012B (en)	2016-04-08	Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
KR20250098360A (ko)	2025-07-01	지혈 및 유착방지 효과가 우수한 창상피복재 조성물 및 이의 용도
OA16780A (en)	2016-01-04	Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process.
Shepard et al.	1996	ICD infection avoidance: science, art, discipline